Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922856 · ClinicalTrials.gov registry record · Phase 2
Challenge Study of an ETEC Vaccine
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01922856 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 56 participants.
The verdict
NCT01922856, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of a vaccine against enterotoxigenic E. coli (ETEC)-caused diarrhea.
Interventions
- OTHER No Intervention
- BIOLOGICAL LTR192G with dscCfaE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-09-19 |
| Est. Completion | 2016-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01922856
The ClinicalTrials.gov registry entry for NCT01922856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No Intervention is the first listed.
NCT01922856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01922856 about?
NCT01922856 is a clinical study titled "Challenge Study of an ETEC Vaccine". The purpose of the study is to determine the efficacy of a vaccine against enterotoxigenic E. coli (ETEC)-caused diarrhea.
What is the current status of trial NCT01922856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2013-09-19. Estimated completion is 2016-07-14.
What interventions are being tested in trial NCT01922856?
The interventions under investigation include: No Intervention (OTHER), LTR192G with dscCfaE (BIOLOGICAL).
Who is sponsoring clinical trial NCT01922856?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.